Glucose control in non-critically ill inpatients with diabetes: Towards closed-loop

Diabetes, Obesity and Metabolism

Volumn 16, Issue 6, 2014, Pages 500-509

  Thabit, H ^a   Hovorka, R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Closed loop system; Computerized ordering; General wards; Glucose monitoring; Inpatient hyperglycaemia; Insulin therapy; Non critical care; Technology

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; HEALTH CARE PERSONNEL; HOSPITAL PATIENT; HOSPITAL PERSONNEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; KNOWLEDGE; MEDICAL TECHNOLOGY; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; TREATMENT PLANNING; WORKLOAD; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; SEVERITY OF ILLNESS INDEX;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; SEVERITY OF ILLNESS INDEX;

EID: 84899629765     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12228     Document Type: Review

References (105)

1. Tomlin AM, Tilyard MW, Dovey SM, Dawson AG. Hospital admissions in diabetic and non-diabetic patients: a case-control study. Diabetes Res Clin Pract 2006; 73: 260-267.
2. Kerr M. Inpatient care for people with diabetes. The economic case for change. 2011. Available from URL: www.diabetes.nhs.uk. Accessed 20 June 2013.
3. National Diabetes Inpatient Audit. Health and Social Care Information Centre (HSCIC) NHS UK. 2011. Available from URL: http://www.ic.nhs.uk/diabetesinpatientaudit. Accessed 20 June 2013.
4. Wexler DJ, Meigs JB, Cagliero E, Nathan DM, Grant RW. Prevalence of hyper- and hypoglycemia among inpatients with diabetes: a national survey of 44 U.S. hospitals. Diabetes Care 2007; 30: 367-369.
5. American Diabetes Association, Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008; 31: 596-615.
6. Wang W, McGreevey WP, Fu C et al. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care 2009; 15: 593-601.
7. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002; 87: 978-982.
8. Baker EH, Janaway CH, Philips BJ et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006; 61: 284-289.
9. Sarkisian S, Fenton TR, Shaheen AA, Raman M. Parenteral nutrition-associated hyperglycemia in noncritically ill inpatients is associated with higher mortality. Can J Gastroenterol 2010; 24: 453-457.
10. Dhatariya K. Should inpatient hyperglycaemia be treated? BMJ 2013; 346: f134.
11. Umpierrez GE, Smiley D, Jacobs S et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011; 34: 256-261.
12. Malmberg K, Rydén L, Hamsten A, Herlitz J, Waldenström A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J. 1996; 17: 1337-1344.
13. Ahmann A. Reduction of hospital costs and length of stay by good control of blood glucose levels. Endocr Pract 2004; 10(Suppl. 2): 53-56.
14. Boord JB, Greevy RA, Braithwaite SS et al. Evaluation of hospital glycemic control at US academic medical centers. J Hosp Med 2009; 4: 35-44.
15. National Diabetes Inpatient Audit. Health and Social Care Information Centre (HSCIC) NHS UK. 2011:1-53. Available from URL: http://www.ic.nhs.uk/diabetesinpatientaudit. Accessed 10 February 2013.
16. Griesdale DE, de Souza RJ, van Dam RM et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009; 180: 821-827.
17. Van den Berghe G. Intensive insulin therapy in the ICU-reconciling the evidence. Nat Rev Endocrinol 2012; 8: 374-378.
18. Umpierrez GE, Hellman R, Korytkowski MT et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 16-38.
19. Juneja R. Hyperglycemia management in the hospital: about glucose targets and process improvements. Postgrad Med 2008; 120: 38-50.
20. Moghissi ES. Addressing hyperglycemia from hospital admission to discharge. Curr Med Res Opin 2010; 26: 589-598.
21. Umpierez GE. How to manage type 2 diabetes in medical and surgical patients in the hospital. Cleve Clin J Med 2011; 78: 379-384.
22. Murad MH, Coburn JA, Coto-Yglesias F et al. Glycemic control in non-critically ill hospitalized patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97: 49-58.
23. Wexler DJ. Inpatient diabetes management in general medical and surgical settings: evidence and update. Expert Rev Pharmacoecon Outcomes Res 2007; 7: 491-502.
24. Hellman R. Patient safety and inpatient glycemic control: translating concepts into action. Endocr Pract 2006; 12(Suppl. 3): 49-55.
25. Pichardo-Lowden A, Gabbay RA. Management of hyperglycemia during the perioperative period. Curr Diab Rep 2012; 12: 108-118.
26. Latta S, Alhosaini MN, Al-Solaiman Y et al. Management of inpatient hyperglycemia: assessing knowledge and barriers to better care among residents. Am J Ther 2011; 18: 355-365.
27. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet 2009; 373: 1798-1807.
28. Evans NR, Dhatariya KK. Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. Clin Med 2012; 12: 137-139.
29. Nirantharakumar K, Marshall T, Kennedy A, Narendran P, Hemming K, Coleman JJ. Hypoglycaemia is associated with increased length of stay and mortality in people with diabetes who are hospitalized. Diabet Med 2012; 29: e445-e448.
30. Brodovicz KG, Mehta V, Zhang Q et al. Association between hypoglycemia and inpatient mortality and length of hospital stay in hospitalized, insulin-treated patients. Curr Med Res Opin 2013; 29: 101-107.
31. Draznin B, Gilden J, Golden SH et al. Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action. Diabetes Care 2013; 36: 1807-1814.
32. Sampson MJ, Crowle T, Dhatariya K et al. Trends in bed occupancy for inpatients with diabetes before and after the introduction of a diabetes inpatient specialist nurse service. Diabet Med 2006; 23: 1008-1015.
33. George JT, Warriner D, McGrane DJ et al. Lack of confidence among trainee doctors in the management of diabetes: the Trainees Own Perception of Delivery of Care (TOPDOC) Diabetes Study. QJM 2011; 104: 761-766.
34. Kavanagh BP. Glucose in the ICU-evidence, guidelines, and outcomes. N Engl J Med 2012; 367: 1259-1260.
35. Pichardo-Lowden AR, Fan CY, Gabbay RA. Management of hyperglycemia in the non-intensive care patient: featuring subcutaneous insulin protocols. Endocr Pract 2011; 17: 249-260.
36. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009; 32: 1153-1157.
37. Dhatariya K, Hilton L, Klivert A, Levy N, Rayman G, Watson B. Management of Adults with Diabetes Undergoing Surgery and Elective Procedures: Improving Standards. London: Joint British Diabetes Societies Inpatient Care Group for NHS Diabetes, 2011. Available from URL: http://www.diabetes.nhs.uk/our_publications/reports_and_guidance/inpatient_and_emergency. Accessed 25 August 2013.
38. Hsia E, Seggelke S, Gibbs J et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab 2012; 97: 3132-3137.
39. Simpson S, Packer C, Stevens A, Raftery J. Predicting the impact of new health technologies on average length of stay: development of a prediction framework. Int J Technol Assess Health Care 2005; 21: 487-491.
40. Vanhorebeek I, Langouche L. Molecular mechanisms behind clinical benefits of intensive insulin therapy during critical illness: glucose versus insulin. Best Pract Res Clin Anaesthesiol 2009; 23: 449-459.
41. Siebenhofer A, Plank J, Berghold A et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006: CD003287.
42. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009; 180: 400-407.
43. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
44. Leichter S. Is the use of insulin analogues cost-effective? Adv Ther 2008; 25: 285-299.
45. Joslin E. A Diabetic Manual for the Mutual Use of Doctor and Patient. 5 edn. Philadelphia: Lea & Febiger, 1934.
46. Nau KC, Lorenzetti RC, Cucuzzella M, Devine T, Kline J. Glycemic control in hospitalized patients not in intensive care: beyond sliding-scale insulin. Am Fam Physician 2010; 81: 1130-1135.
47. Roberts GW, Aguilar-Loza N, Esterman A, Burt MG, Stranks SN. Basal-bolus insulin versus sliding-scale insulin for inpatient glycaemic control: a clinical practice comparison. Med J Aust 2012; 196: 266-269.
48. Umpierrez GE, Smiley D, Zisman A et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007; 30: 2181-2186.
49. Rutter CL, Jones C, Dhatariya KK et al. Determining in-patient diabetes treatment satisfaction in the UK-the DIPSat study. Diabet Med 2013; 30: 731-738.
50. Moghissi ES, Korytkowski MT, DiNardo M et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009; 32: 1119-1131.
51. Dhatariya K, Levy N, Kilvert A et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabet Med 2012; 29: 420-433.
52. Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy 2012; 32: 613-617.
53. Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013; 39: 179-190.
54. Govindan J, Evans M. Pioglitazone in clinical practice: where are we now? Diabetes Ther 2012; 3: 1-8.
55. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006; 355: 1903-1911.
56. Edwards KL, Stapleton M, Weis J, Irons BK. An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists. Diabetes Technol Ther 2012; 14: 951-967.
57. Mecott GA, Herndon DN, Kulp GA et al. The use of exenatide in severely burned pediatric patients. Crit Care 2010; 14: R153.
58. Abuannadi M, Kosiborod M, Riggs L et al. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract 2013; 19: 81-90.
59. Meier JJ, Weyhe D, Michaely M et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004; 32: 848-851.
60. Umpierrez GE, Korytkowski M. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: insulin therapy has proven itself and is considered the mainstay of treatment. Diabetes Care 2013; 36: 2112-2117.
61. Schwartz S, DeFronzo RA. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: the time has come for GLP-1 receptor agonists!. Diabetes Care 2013; 36: 2107-2111.
62. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013; 36: 2118-2125.
63. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 2013; 36: 2126-2132.
64. Tonyushkina K, Nichols JH. Glucose meters: a review of technical challenges to obtaining accurate results. J Diabetes Sci Technol 2009; 3: 971-980.
65. Krouwer JS, Cembrowski GS. A review of standards and statistics used to describe blood glucose monitor performance. J Diabetes Sci Technol 2010; 4: 75-83.
66. European Committee for Standardisation. In vitro diagnostic test systems- Requirements for blood glucose monitoring systems for self-testing in managing diabetes mellitus (ISO 15197). 2013
67. Nichols JH. Blood glucose testing in the hospital: error sources and risk management. J Diabetes Sci Technol 2011; 5: 173-177.
68. Cook CB, Moghissi E, Joshi R, Kongable GL, Abad VJ. Inpatient point-of-care bedside glucose testing: preliminary data on use of connectivity informatics to measure hospital glycemic control. Diabetes Technol Ther 2007; 9: 493-500.
69. Buchs AE, Rapoport MJ. Institutional glucometrics to determine glucose control as practiced by general medicine wards. Isr Med Assoc J 2010; 12: 463-467.
70. Inoue S, Egi M, Kotani J, Morita K. Accuracy of blood-glucose measurements using glucose meters and arterial blood gas analyzers in critically ill adult patients: systematic review. Crit Care 2013; 17: R48.
71. Hoedemaekers CW, Klein Gunnewiek JM, Prinsen MA, Willems JL, Van der Hoeven JG. Accuracy of bedside glucose measurement from three glucometers in critically ill patients. Crit Care Med 2008; 36: 3062-3066.
72. Fahy BG, Coursin DB. Critical glucose control: the devil is in the details. Mayo Clinic Proc 2008; 83: 394-397.
73. Schnipper JL, Liang CL, Ndumele CD, Pendergrass ML. Effects of a computerized order set on the inpatient management of hyperglycemia: a cluster-randomized controlled trial. Endocr Pract 2010; 16: 209-218.
74. Schnipper JL, Ndumele CD, Liang CL, Pendergrass ML. Effects of a subcutaneous insulin protocol, clinical education, and computerized order set on the quality of inpatient management of hyperglycemia: results of a clinical trial. J Hosp Med 2009; 4: 16-27.
75. Maynard G, Lee J, Phillips G, Fink E, Renvall M. Improved inpatient use of basal insulin, reduced hypoglycemia, and improved glycemic control: effect of structured subcutaneous insulin orders and an insulin management algorithm. J Hosp Med 2009; 4: 3-15.
76. Munasinghe RL, Arsene C, Abraham TK, Zidan M, Siddique M. Improving the utilization of admission order sets in a computerized physician order entry system by integrating modular disease specific order subsets into a general medicine admission order set. J Am Med Inform Assoc 2011; 18: 322-326.
77. Wei NJ, Wexler DJ. Basal-bolus insulin protocols enter the computer age. Curr Diab Rep 2012; 12: 119-126.
78. Nirantharakumar K, Chen YF, Marshall T, Webber J, Coleman JJ. Clinical decision support systems in the care of inpatients with diabetes in non-critical care setting: systematic review. Diabet Med 2012; 29: 698-708.
79. Wexler DJ, Shrader P, Burns SM, Cagliero E. Effectiveness of a computerized insulin order template in general medical inpatients with type 2 diabetes: a cluster randomized trial. Diabetes Care 2010; 33: 2181-2183.
80. Guerra YS, Das K, Antonopoulos P et al. Computerized physician order entry- based hyperglycemia inpatient protocol and glycemic outcomes: the CPOE-HIP study. Endocr Pract 2010; 16: 389-397.
81. Mader JK, Neubauer KM, Schaupp L et al. Efficacy, usability and sequence of operations of a workflow-integrated algorithm for basal-bolus insulin therapy in hospitalized type 2 diabetes patients. Diabetes Obes Metab 2013; DOI: 10.1111/dom.12186 [Epub ahead of print].
82. Moxey A, Robertson J, Newby D, Hains I, Williamson M, Pearson SA. Computerized clinical decision support for prescribing: provision does not guarantee uptake. J Am Med Inform Assoc 2010; 17: 25-33.
83. Aragon D. Evaluation of nursing work effort and perceptions about blood glucose testing in tight glycemic control. Am J Crit Care 2006; 15: 370-377.
84. Oliver NS, Toumazou C, Cass AE, Johnston DG. Glucose sensors: a review of current and emerging technology. Diabet Med 2009; 26: 197-210.
85. Heller A, Feldman B. Electrochemical glucose sensors and their applications in diabetes management. Chem Rev 2008; 108: 2482-2505.
86. Keenan DB, Mastrototaro JJ, Voskanyan G, Steil GM. Delays in minimally invasive continuous glucose monitoring devices: a review of current technology. J Diabetes Sci Technol 2009; 3: 1207-1214.
87. Buckingham B, Chase HP, Dassau E et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care 2010; 33: 1013-1017.
88. Aussedat B, Dupire-Angel M, Gifford R, Klein JC, Wilson GS, Reach G. Interstitial glucose concentration and glycemia: implications for continuous subcutaneous glucose monitoring. Am J Physiol Endocrinol Metab 2000; 278: E716-E728.
89. Kovatchev BP, Shields D, Breton M. Graphical and numerical evaluation of continuous glucose sensing time lag. Diabetes Technol Ther 2009; 11: 139-143.
90. Leelarathna L, Nodale M, Allen JM et al. Evaluating the accuracy and large inaccuracy of two continuous glucose monitoring systems. Diabetes Technol Ther 2013; 15: 143-149.
91. Holzinger U, Warszawska J, Kitzberger R et al. Real-time continuous glucose monitoring in critically ill patients: a prospective randomized trial. Diabetes Care 2010; 33: 467-472.
92. Ryan MT, Savarese VW, Hipszer B et al. Continuous glucose monitor shows potential for early hypoglycemia detection in hospitalized patients. Diabetes Technol Ther 2009; 11: 745-747.
93. Klonoff DC, Buckingham B, Christiansen JS et al. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 2968-2979.
94. Kopecký P, Mráz M, Bláha J et al. The use of continuous glucose monitoring combined with computer-based eMPC algorithm for tight glucose control in cardiosurgical ICU. Biomed Res Int. 2013; 2013: 186439.
95. Jacobs B, Phan K, Bertheau L, Dogbey G, Schwartz F, Shubrook J. Continuous glucose monitoring system in a rural intensive care unit: a pilot study evaluating accuracy and acceptance. J Diabetes Sci Technol 2010; 4: 636-644.
96. Lorencio C, Leal Y, Bonet A et al. Real-time continuous glucose monitoring in an intensive care unit: better accuracy in patients with septic shock. Diabetes Technol Ther 2012; 14: 568-575.
97. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011; 7: 385-395.
98. Phillip M, Battelino T, Atlas E et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013; 368: 824-833.
99. Elleri D, Allen JM, Kumareswaran K et al. Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 Diabetes: Randomized clinical trial. Diabetes Care 2013; 36: 838-844.
100. Haidar A, Legault L, Dallaire M et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ. 2013; 185: 297-305.
101. Weinzimer SA. Closed-loop artificial pancreas: current studies and promise for the future. Curr Opin Endocrinol Diabetes Obes 2012; 19: 88-92.
102. Tsukamoto Y, Kinoshita Y, Kitagawa H et al. Evaluation of a novel artificial pancreas: closed loop glycemic control system with continuous blood glucose monitoring. Artif Organs 2013; 37: E67-E73.
103. Okabayashi T, Nishimori I, Maeda H, Yamashita K, Yatabe T, Hanazaki K. Effect of intensive insulin therapy using a closed-loop glycemic control system in hepatic resection patients: a prospective randomized clinical trial. Diabetes Care 2009; 32: 1425-1427.
104. Kumareswaran K, Thabit H, Leelarathna L et al. Feasibility of closed-loop insulin delivery in type 2 diabetes: a randomised controlled study. Diabetes Care 2013; DOI: 10.2337/dc13-1030 [Epub ahead of print].
105. Leelarathna L, English SW, Thabit H et al. Feasibility of fully automated closed-loop glucose control utilizing continuous subcutaneous glucose measurements in critical illness: a randomised controlled trial. Crit Care 2013; 17: R159.